| |
Puerto Rico offers top-notch talent, smart tax incentives & a robust supply chain, making it a bioscience powerhouse. With the highest concentration of pharma & medical device talent in the U.S., & extensive tax benefits, it’s the top destination for innovation. Visit our booth at BIO to learn more. 
|
|
Today’s Big NewsJun 7, 2024 |
| By Kevin Dunleavy The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech. |
|
|
|
By Nick Paul Taylor Biomea Fusion has suffered another dramatic stock drop, with investors sending the share price down 60% after the FDA imposed a full clinical hold on its diabetes program over liver toxicity concerns. |
By Conor Hale Nearly a year after garnering an FDA nod, Abbott’s wireless, dual-chamber pacemaker system is crossing the pond with a CE Mark approval in Europe. |
By Nick Paul Taylor Eisai and Biogen’s reign at the top of the Alzheimer’s disease market may be short-lived. While Leqembi is the only game in town today, Bloomberg Intelligence analysts expect Eli Lilly to come from behind and capture half of a $13 billion market by 2030. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Zoey Becker Priya Bhambi, 40, pled guilty to wire fraud charges after running a detailed scheme to scam Takeda into paying for non-existent services from a fake consulting firm. |
By Nick Paul Taylor Ipsen is hot on Marengo Therapeutics’ ability to treat “cold” tumors. The French drugmaker has agreed to pay Marengo up to $1.2 billion to access a T-cell engager platform for targeting immunologically cold tumors that are typically resistant to immunotherapies. |
By Conor Hale After previewing its agreement earlier this year, the laparoscopic robotics developer Asensus Surgical has made its buyout official. |
By Angus Liu In an interview with Fierce Pharma, BIO CEO John Crowley maintained that "biotech is a national security imperative" for the U.S., but he also took a softer tone and voiced a desire for the U.S.-China tensions to ease. He argued that any further additions to the proposed BIOSECURE Act would have to be based on "very clear and convincing evidence." |
By Gabrielle Masson Just a few days after Rapport Therapeutics revealed plans for a $122 million IPO, the epilepsy biotech has unveiled an upsized $154 million offering. |
By Conor Hale Medtronic said the problem lies in the on-screen displays of submillimeter-sensitive information such as “distance to target” or “tip stop point,” which guides the depth of a biopsy needle. |
By Gabrielle Masson,Andrea Park Several Sanofi leaders are scattering, including Frank Nestle, M.D., the French pharma’s global head of research and chief scientific officer. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us for a one-hour discussion on oral cyclic peptide drug development. Learn about key breakthroughs that demonstrate results. Register now. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
